Notice of Cipher Pharmaceuticals Inc. Q1 2014 conference call and 2013 Annual General Meeting of Shareholders

MISSISSAUGA, ON, April 21, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced it will host a conference call for its Q1 2014 financial results and hold its Annual General Meeting of Shareholders on Friday, May 2, 2014.

Q1 2014 CONFERENCE CALL

WHEN: Friday, May 2, 2014 at 8:30AM ET

CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://bit.ly/1eO4nJg. An archived replay of the webcast will be available for 365 days.

ANNUAL GENERAL MEETING OF SHAREHOLDERS

WHEN: Friday, May 2, 2014 at 11:00AM ET

WHERE: Goodmans LLP, Bay Adelaide Centre, 333 Bay Street, Suite 3400, Toronto, Ontario

WEBCAST: The meeting will be webcast live. To access the webcast go to http://www.cipherpharma.com or http://bit.ly/1r2Pcf2. Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.

SOURCE: Cipher Pharmaceuticals Inc.

Craig Armitage
Investor Relations
TMX Equicom
[phone] ext 278
[phone] fax
[email protected] 

Norm Evans
Chief Financial Officer
Cipher Pharmaceuticals
[phone] ext 323
[phone] fax
[email protected]